Research Article

Risk of Cardiovascular Diseases in Diabetes Mellitus and Serum Concentration of Asymmetrical Dimethylarginine

Seema L. Jawalekar, 1 Aarti Karnik, 2 and Anil Bhuity 3

1 Department of Biochemistry, Sree Narayana Institute of Medical Sciences, Chalakka, Ernakulam, Kerala, India
2 Department of Biochemistry, ACPM Medical College, Dhule, Maharashtra, India
3 Department of Biochemistry, Panjabrao Deshmukh Medical College, Amravati, Maharashtra, India

Correspondence should be addressed to Seema L. Jawalekar; seems2april@rediffmail.com

Received 2 July 2013; Revised 25 August 2013; Accepted 25 August 2013

Copyright © 2013 Seema L. Jawalekar et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Introduction. Asymmetric dimethylarginine (ADMA) is a nonselective nitric oxide (NO) synthase inhibitor associated with cardiovascular and metabolic disorders. ADMA plays an important role in the regulation of vascular tone by acting as an endogenous inhibitor of NO synthesis. Objectives. This study aimed to investigate ADMA with respect to diabetes and its clinical relevance as an independent predictor of CAD (Coronary Artery Disease). Methodology. The present case control study includes two hundred and forty patients selected randomly. Serum ADMA was analyzed by using enzyme immunoassay for the quantitative determination of endogenous ADMA, and serum nitric oxide was estimated by the method of Cortes. Results. Elevated NO level was a strong predictor and significantly ($t$: 9.86, $P < 0.001$) associated with occurrence of CAD. Increased ADMA level was found to be another strong predictor and associated significantly ($t$: 8.02, $P < 0.001$) with CAD. On intra group analysis, the relationship between ADMA and NO in diseased group, is significant negative correlation ($r = −0.743$, $P (0.001)$ was found between ADMA and NO. Conclusion. ADMA level was found to be one of the strong predictors for CAD. ADMA is an emerging independent risk marker for future CVD (cardiovascular disease) events.

1. Introduction

Cardiovascular disease (CVD) is the major cause of morbidity and mortality in patients with diabetes mellitus (DM). Diabetes is at high risk for several cardiovascular disorders: coronary heart disease, stroke, peripheral arterial disease, cardiomyopathy, and congestive heart failure [1–3]. Endothelial dysfunction is a common feature in diabetic patients and may contribute to cardiovascular morbidity [4–6]. Mechanisms of diabetes-induced endothelial dysfunction include the production of prostanooid vasoconstrictors and the increased oxidative degradation of NO [7, 8]. Deficiency of NO increases vascular resistance and promotes atherogenesis [9].

Nitric oxide (NO) is a very active but short lived, a molecule that is released into the circulation from endothelial cells. It is a potent vasodilator that regulates vascular resistance and tissue blood flow. In addition, NO inhibits key processes of atherosclerosis, such as monocyte endothelial adhesion, platelet aggregation, and vascular smooth muscle cell proliferation. Hence, endothelial dysfunction due to reduced NO availability is an early step in the course of atherosclerotic vascular disease [10]. NO is synthesized by stereospecific oxidation of the terminal guanidino nitrogen of the amino acid, L-arginine, by the action of a family of NOS. Since NO has tremendous biological activity, its blood and/or tissue concentration must be kept within narrow limits in order to prevent harmful effects on cell activity. The synthesis of NO can be blocked, however, by inhibition of the NOS active site with guanidino-substituted analogs of L-arginine, such as asymmetrical dimethylarginine (ADMA) [10].

ADMA is a naturally occurring amino acid that has the interesting property of competitively inhibiting the activity of nitric oxide synthase (NOS). ADMA is produced by methylation of arginine residues in intracellular proteins via protein arginine N-methyltransferases (PRMT).
After hydrolyzation of proteins, results into release of ADMA. ADMA is excreted in the urine, and, not surprisingly, there is an increase in plasma ADMA in patients with end-stage renal disease [11]. Parenthetically, patients with renal disease have an increased risk of cardiovascular morbidity and mortality, and in these patient’s plasma ADMA concentrations carry prognostic information [12].

The primary route of ADMA clearance, however, is by enzymatic degradation. Dimethylamine dimethylaminohydrolase (DDAH) converts ADMA to citrulline and dimethylamine. By regulating the plasma and tissue concentrations of ADMA, NOS activity is protected by DDAH [13].

Recently, it has been demonstrated that plasma levels of ADMA are elevated in patients with diabetes mellitus [7]. These findings suggest that the elevated ADMA in diabetes could contribute to accelerated atherosclerosis in this population. Further, as ADMA is mainly metabolized by dimethylarginine dimethylaminohydrolase (DDAH), it is conceivable that the inhibition of ADMA via upregulation of DDAH may be a novel therapeutic target for the prevention of CVD in patients with diabetes.

Under experimental conditions that lead to suboptimal L-arginine concentrations or to a relative deficiency of essential cofactors for NO synthase, the activity of this enzyme is “uncoupled.” This means that the oxidation of L-arginine to NO is not complete [14–16]. Normally, five electrons are being transferred in two steps of a coupled reduction-oxidation reaction by the two domains of NO synthase from molecular oxygen to L-arginine, resulting in the release of L-citrulline and NO.

ADMA is elevated to a level that can significantly inhibit NOS activity in individuals with hypercholesterolemia, hypertension, and hyperhomocysteinemia, tobacco exposure, and hyperglycemia [17–19] in each of these conditions; the elevation in ADMA level is a result of oxidative stress. Further oxidative stress impairs the ability of DDAH to metabolize ADMA [17, 20]. Hyperglycemia can elevate intracellular oxidative stress through multiple mechanisms [21, 22].

Under suboptimal conditions like those mentioned above, the electron flow within the two domains of NO synthase is disturbed, and molecular oxygen acts as an electron acceptor. This makes NO synthases a superoxide (O2−) radical-producing enzyme.

The endothelium-derived relaxation factor, nitric oxide, provides a unifying mechanism for the action of many cardiovascular disease risk factors. Nitric oxide cannot be measured directly, but the inhibitor of its formation and asymmetric dimethylarginine (ADMA) can be measured. The function of ADMA in modulating nitric oxide production has a significant impact on cardiovascular endothelial function.

2. Objectives

Asymmetric dimethylarginine (ADMA) is a nonselective nitric oxide (NO) synthase inhibitor associated with cardiovascular and metabolic disorders. This study aimed to investigate ADMA with respect to diabetes and its clinical relevance as an independent predictor of CAD.

3. Materials and Methods

The present case control study includes two hundred and forty patients, selected randomly. After careful clinical examination and confirmed diagnosis, they are further divided into three groups. Group I, patients presenting CVD (n = 80); Group II, patients with type II diabetes mellitus (n = 80); Group III, patients with type II DM with CVD; and a control group (n = 80).

All patients selected underwent medical examination by a physician. A careful medical history was taken to obtain information about other diseases (particularly hypertension, coronary heart disease, myocardial infarction, stroke, peripheral vascular disease and endocrine disorders). Inclusion criteria, and patients clinically diagnosed having angiographically proven CVD with/without type II DM. Prevalence of diabetes was assessed either by fasting blood glucose level ≥126.0 mg/dL or HbA1C levels more than 6%. Exclusion criteria—patients with a history of prior coronary artery bypass grafting and patients with kidney and acute liver diseases were excluded.

Patients matched 80 subjects as control, and group II was randomly selected from patients attending diabetic OPD (Outpatient department). Controls have a negative history of CVD, Type II DM and had a normal resting ECG (Electrocardiogram).

Patients in group I and III were recruited from inpatient and outpatients departments of the hospital. The diagnosis of CVD was made on the basis of the clinical history (typical angina, history of myocardial infarction) and 12—lead standard ECG before subjecting them to coronary angiography. The presence of any stenosis >30% according to coronary angiography by visual assessment of coronary artery was included in the study.

The study was approved by the ethical committee of our institute. Fully informed consent was obtained from patients. Blood samples were drawn into vacutainer tubes. Serum ADMA was analyzed by using enzyme immunoassay for the quantitative determination of endogenous ADMA, [23] and serum nitric oxide was estimated by the method of Cortes [24].

ADMA was analyzed by enzyme linked immunoassay for the quantitative determination of endogenous asymmetric dimethylarginine in serum, manufactured by DLD diagnostics GMBH, which is based on principal, the competitive ADMA-ELISA uses the microtiter plate format. ADMA is bound to the solid phase of the microtiter plate. ADMA in the samples is acetylated and competes with solid phase bound ADMA for a fixed number of rabbit anti-ADMA antiserum binding sites. When the system is in equilibrium, free antigen and free antigen antiserum complexes are removed by washing. The antibody bounded to the solid phase ADMA is detected by the anti-rabbit/peroxidase. The substrate TMB/peroxidase reaction is monitored at 450 nm. The amount of antibody bound to the solid phase ADMA is inversely proportional to the ADMA concentration of the sample.

Statistical analysis was carried by student’s t-test and chi-square test. Results were expressed as mean ± SD. Probability
valuable 0.05 were considered statistically significant. Associations between two categorical variables were tested by means of the $\chi^2$ or Fisher exact tests. All baseline characteristics, presented in Table 1, were evaluated as potential confounders, using univariate Cox regression analysis. All tests were two tailed, and $P < 0.05$ was considered statistically significant. Statistical analysis was performed with SPSS statistical software (V.13.0).

### 4. Results

Patients who had no diabetes mellitus and cardiovascular disease were grouped as control; diabetes with CVD and nondiabetes with CVD are categorized as diseased group and others are categorized as nondiseased group.

Baseline characteristics of the participants are presented in Table 1. The overall mean age for control was 47.0 years, and diseased group was 56.0 years; 74.7% were men. Diabetes with CVD had higher systolic blood pressure and hyperlipidemia than normal healthy subjects. Table 2 shows that type II diabetes with CAD patients have significantly higher ADMA concentration than normal healthy subjects and other study groups $P < 0.001$. NO concentration was lower lowest 26.71 ± 3.41 in DM with CAD patients than the other study groups and normal healthy subjects.

In a multiple logistic regression analysis adjusting for hypertension, hypercholesterolemia, low HDL cholesterol and diabetes fasting glucose, ADMA remained a strong and independent predictor for the presence of CAD. Elevated No level levels was a strong predictor and significantly ($t$: 9.86, $P < 0.001$) associated with occurrence of CAD. Increased ADMA level was found to be another strong predictor and associated significantly ($t$: 8.02, $P < 0.001$) with CAD.

The univariate logistic regression analysis for risk factors versus CVD (as a dependent variable) was done to assess relative risk of development of CVD with each risk factor in the entire study population that includes diseased and nondiseased subjects. Age, family history, obesity, and SBP and DBP are highly significant and associated with CAD pathogenesis (Tables 2, 3, and 4).

### Table 1: Baseline characteristics of the study population.

|                | Control        | Diseased       | $P$ value |
|----------------|----------------|----------------|-----------|
| Age (years)    | 47.29 ± 10.21  | 56.21 ± 6.73   | <0.10     |
| Family history | 13             | 24             | —         |
| Smoker         | 4              | 22             | —         |
| BMI            | 21 (>25)       | 31 (>25)       | —         |
| BP systolic (mm/Hg) | 122.84 ± 3.45 | 132.53 ± 7.62 | <0.01     |
| BP diastolic (mm/Hg) | 80.14 ± 5.53  | 86.23 ± 6.54  | <0.20     |
| FBSL (mg/dL)   | 95.60 ± 18.38  | 132.80 ± 32    | <0.01     |
| HbA1C          | 6.0 ± 1.27     | 7.32 ± 2.46    | <0.50     |
| Total cholesterol | 159.86 ± 26.98 | 282.36 ± 28    | <0.01     |
| HDL (mg/dL)    | 44.21 ± 8.35   | 28.67 ± 8.89   | <0.01     |
| LDL (mg/dL)    | 102.02 ± 25.78 | 159.69 ± 29.65 | <0.05     |
| VLDL (mg/dL)   | 32.98 ± 10.43  | 45.31 ± 14.30  | <0.02     |
| TG (mg/dL)     | 172.67 ± 56.87 | 227.38 ± 68.79 | <0.01     |
ADMA were increased from 1.1 to 2.4, indicating ADMA inhibition of NO production [39]. ADMA plays an important role in the pathogenesis of hypertension associated with the experimental focal and segmental glomerulosclerosis [40].

ADMA is released after posttranslational methylation from nuclear proteins involved in RNA processing and transcriptional control. The enzyme protein arginine methyltransferase type I (PRMT I) forms ADMA, whereas PRMT II forms symmetric dimethylarginine (SDMA) (i.e., the stereoisomer of ADMA with no known effect on NOS). Other data suggests that human endothelial cell PRMT activity is upregulated by LDL cholesterol, due in part to the enhanced gene expression of PRMTs [37]. Thus, we find ADMA intermeshed with both cholesterol, and homocysteine cardiovascular risk factors. Hyperglycemia is another factor related to ADMA. Human endothelial cells exposed to high glucose concentrations show impairment of DDAH and accumulation of ADMA that may contribute to endothelial vasodilator dysfunction in diabetes mellitus [31]. Improved glycemic control in patients with type 2 diabetes results in lowering of plasma ADMA levels.

As ADMA directly impairs the physiological NO-dependent functions of the endothelial lining, its primary pathophysiological mechanism of action is different from all other known risk factors like hypertension (pressure overload of the arterial wall and reduced arterial elasticity), hypercholesterolemia (uptake of (oxidized) LDL into the intimal layer, generation of foam cells, and local inflammation), smoking (induction and potentiation of oxidative damage of cellular structures within the arterial wall). Accordingly, it can be expected that the deleterious effects of ADMA are independent of other risk factors and add to their effects.

In our study, ADMA level was found to be one of the strong predictors for CAD. Another group of investigators from The Netherlands studied the survival of patients undergoing intensive care unit treatment and aimed to identify novel risk factors for survival during ICU treatment [41]. Among all biochemical markers of organ function and disease risk that were measured in this study, ADMA was the factor with the highest predictive power. Patients with elevated ADMA levels had a 17-fold increased risk of fatality during ICU treatment [41].

Understanding of the pathophysiological role of ADMA for the development of cardiovascular diseases, this molecule has become a novel goal for therapeutic intervention. ADMA plays an important role in the regulation of vascular tone by acting as an endogenous inhibitor of NO synthesis. By inhibiting NO synthesis, plasma ADMA may reduce vascular compliance, increase vascular resistance, and limit blood flow. Furthermore, plasma ADMA may promote atherogenesis as it opposes the vasoprotective effects of NO. Thus, elevations in plasma ADMA may accelerate the progression of complications in people with diabetes [30]. Patients with diabetes have an adverse cardiovascular risk profile. Elevated ADMA concentration has been described in patients with type 2 and type 1 diabetes [25]. Hyperglycemia probably may increase ADMA concentration. One invite study demonstrated that elevated glucose levels are capable of inhibiting DDAH activity in cultured endothelial cells [31]. Clinical investigations in patients also indicate that ADMA is directly related to blood glucose levels [25, 32]. As demonstrated in a recent study, strict glycemic control may exert antiatherogenic effects by reducing ADMA levels in patients with type 2 diabetes [33]. Consistent with these studies, the present study provide evidence that elevated serum ADMA and reduced NO independently associated with cardiovascular risk in diabetes patients with coronary artery disease. ADMA might act as pathophysiologically relevant factor for diabetes associated complications. Nevertheless, hyperglycemia remains a major cause for both increased ADMA and the development of diabetic complications which makes the interpretation of the data more complex.

ADMA was that atherosclerosis is marked by impaired vasodilation in response to normal physiological stimuli, and the impairment can be relieved by intravenous L-arginine [34]. A number of standard heart disease risk factors (smoking, hypertension, hyperlipidemias) are related to vasodilatory impairment, but the strongest correlation may be the ADMA in plasma [35]. Elaboration of endothelium-derived nitric oxide affects the behaviour of circulating T lymphocytes and monocytes. Mononuclear cell adhesiveness is inversely correlated with the plasma ADMA, and the effect is reversed by restoration of the ratio-to-control levels with oral administration of 14–21 grams of arginine [36]. These changes lead to lower rates of atherosclerotic plaque formation and lower risk of heart disease. In addition, the association of elevated LDL cholesterol with increased risk of heart disease may be a covariable in the oxidative activation of ADMA synthesis. Oxidized LDL particles stimulate the expression of enzymes that generate ADMA [37].

ADMA may contribute to abnormal blood flow responses and to atherogenesis in type 2 diabetics [38]. In hypertensives, the urinary excretion rate of nitrite plus nitrate (NOx), an index of endogenous NO production, was lowered from 77 to 56 micromol/mmol creatinine, while plasma levels of

| Variables | Control | Group I | Group II | Group III | F     | P value |
|-----------|---------|---------|----------|-----------|-------|---------|
| NO μmol/L | 52.36 ± 6.09 | 32.01 ± 5.005 | 43 ± 8.62 | 26.71 ± 3.41 | 120.8 | 0.001   |
| ADMA μmol/L | 0.36 ± 0.30 | 0.66 ± 0.76 | 0.49 ± 0.28 | 0.78 ± 0.83 | 7633 | 0.001   |

### Table 2: Risk factors.

| Variable | Diseased group | Nondiseased group | $\chi^2$ | P value |
|----------|----------------|-------------------|---------|---------|
| NO <30.00 μmol/L | 52.6 ± 7.79 | 27.38 ± 4.06 | 80.44 | <0.0001 |
| ADMA >0.60 μmol/L | 0.40 ± 0.65 | 0.69 ± 0.85 | 135.1 | <0.0001 |

### Table 3: Parameters taking CAD as dependent variable.
of atherosclerosis and increase the risk of cardiovascular events.

In conclusion, ADMA is an emerging independent risk marker for future CVD events. The clinical acceptance of this parameter will depend on the availability of a therapy to directly decrease ADMA, which could then confirm the role of ADMA as a causal risk factor. Further studies are warranted in patients with diabetes, especially regarding the possible effects of ADMA on diabetes associated complications.

**Abbreviations**

ADMA: Asymmetric dimethylarginine  
CAD: Coronary artery disease  
CVD: Cardiovascular disease  
DM: Diabetes mellitus  
DDAH: Dimethylamine dimethylaminohydrolase  
ECG: Electrocardiogram  
NO: Nitric oxide  
NOS: Nitric oxide synthase  
OPD: Outpatient department  
PRMT: Protein arginine N-methyltransferases.

**References**

[1] R. Candido, P. Srivastava, M. E. Cooper, and L. M. Burrell, “Diabetes mellitus: a cardiovascular disease,” *Current Opinion in Investigational Drugs*, vol. 4, no. 9, pp. 1088–1094, 2003.

[2] Expert Committee on the Diagnosis and Classification of Diabetes Mellitus, “Report of the expert committee on the diagnosis and classification of diabetes mellitus,” *Diabetes Care*, vol. 22, supplement 1, pp. S5–S19, 1999.

[3] A. D. Mooradian, “Cardiovascular disease in type 2 diabetes mellitus: current management guidelines,” *Archives of Internal Medicine*, vol. 163, no. 1, pp. 33–40, 2003.

[4] H. Miyazaki, H. Matsuoka, J. P. Cooke et al., “Endogenous nitric oxide synthase inhibitor: a novel marker of atherosclerosis,” *Circulation*, vol. 99, no. 9, pp. 1141–1146, 1999.

[5] V. Schächinger, M. B. Britten, and A. M. Zeiher, “Prognostic impact of coronary vasodilator dysfunction on adverse long-term outcome of coronary heart disease,” *Circulation*, vol. 101, no. 16, pp. 1899–1906, 2000.

[6] J. A. Suwaidi, S. Hamasaki, S. T. Higano, R. A. Nishimura, D. R. Holmes Jr., and A. Lerman, “Long-term follow-up of patients with mild coronary artery disease and endothelial dysfunction,” *Circulation*, vol. 101, no. 9, pp. 948–954, 2000.

[7] C. Nielson and T. Lange, “Blood glucose and heart failure in nondiabetic patients,” *Diabetes Care*, vol. 28, no. 3, pp. 607–611, 2005.

[8] B. Tesfamariam, M. L. Brown, and R. A. Cohen, “15-Hydroxyeicosatetraenoic acid and diabetic endothelial dysfunction in rabbit aorta,” *Journal of Cardiovascular Pharmacology*, vol. 25, no. 5, pp. 748–755, 1995.

[9] J. P. Cooke and V. J. Dzau, “Nitric oxide synthase: role in the genesis of vascular disease,” *Annual Review of Medicine*, vol. 48, pp. 489–509, 1997.

[10] J. P. Cooke, “Does ADMA cause endothelial dysfunction?” *Arteriosclerosis, Thrombosis, and Vascular Biology*, vol. 20, no. 9, pp. 2032–2037, 2000.

[11] J. T. Kielstein, R. H. Böger, S. M. Bode-Böger et al., “Asymmetric dimethylarginine plasma concentrations differ in patients with end-stage renal disease: relationship to treatment method and atherosclerotic disease,” *Journal of the American Society of Nephrology*, vol. 10, no. 3, pp. 594–600, 1999.

[12] C. Zoccali, S. M. Bode-Böger, F. Mallamaci et al., “Plasma concentration of asymmetrical dimethylarginine and mortality in patients with end-stage renal disease: a prospective study,” *Lancet*, vol. 358, no. 9299, pp. 2113–2117, 2001.

[13] H. Dayoub, V. Achan, S. Adimoolam et al., “Dimethylarginine dimethylaminohydrolase regulates nitric oxide synthesis: genetic and physiological evidence,” *Circulation*, vol. 108, no. 24, pp. 3042–3047, 2003.

[14] P. Klatt, K. Schmidt, G. Uray, and B. Mayer, “Multiple catalytic functions of brain nitric oxide synthase,” *Journal of Biological Chemistry*, vol. 268, no. 20, pp. 14781–14787, 1993.

[15] J. Vásquez-Vivar, B. Kalyanaraman, P. Martásek et al., “Superoxide generation by endothelial nitric oxide synthase: the influence of cofactors,” *Proceedings of the National Academy of Sciences of the United States of America*, vol. 95, no. 16, pp. 9220–9225, 1998.

[16] K. A. Pritchard Jr., L. Groszek, D. M. Smalley et al., “Native low-density lipoprotein increases endothelial cell nitric oxide synthase generation of superoxide anion,” *Circulation Research*, vol. 77, no. 3, pp. 510–518, 1995.

[17] R. H. Böger, S. M. Bode-Böger, A. Szuba et al., “Asymmetric dimethylarginine (ADMA): a novel risk factor for endothelial dysfunction: its role in hypercholesterolemia,” *Circulation*, vol. 98, no. 18, pp. 1842–1847, 1998.

[18] M. C. Stühlinger, P. S. Tsao, J. H. Her, M. Kimoto, R. F. Bulint, and J. P. Cooke, “Homocysteine impairs the nitric oxide synthase pathway role of asymmetric dimethylarginine,” *Circulation*, vol. 104, no. 21, pp. 2569–2575, 2001.

[19] A. Fard, C. H. Tuck, J. A. Donis et al., “Acute elevations of plasma asymmetric dimethylarginine and impaired endothelial
function in response to a high-fat meal in patients with type 2 diabetes,” *Arteriosclerosis, Thrombosis, and Vascular Biology*, vol. 20, no. 9, pp. 2039–2044, 2000.

[20] A. Ito, P. S. Tsao, S. Adimoolam, M. Kimoto, T. Ogawa, and J. P. Cooke, “Novel mechanism for endothelial dysfunction: dysregulation of dimethylarginine dimethylaminohydrolase,” *Circulation*, vol. 99, no. 24, pp. 3092–3095, 1999.

[21] L. A. Powell, S. M. Nally, D. McMaster, M. A. Catherwood, and E. R. Trimble, “Restoration of gluthathione levels in vascular smooth muscle cells exposed to high glucose conditions,” *Free Radical Biology and Medicine*, vol. 31, no. 10, pp. 1149–1155, 2001.

[22] W. C. Duckworth, “Hyperglycemia and cardiovascular disease,” *Current Atherosclerosis Reports*, vol. 3, no. 5, pp. 383–391, 2001.

[23] F. Schulze, R. Wesemann, E. Schwedhelm et al., “Determination of asymmetric dimethylarginine (ADMA) using a novel ELISA assay,” *Clinical Chemistry and Laboratory Medicine*, vol. 42, no. 12, pp. 1377–1383, 2004.

[24] N. K. Cortasand N. W. Wakid, “Determination of inorganic nitrate in serum and urine by a kinetic cadmium-reduction method,” *Clinical Chemistry*, vol. 36, no. 8, pp. 1440–1443, 1990.

[25] F. Abbasi, T. Asagami, J. P. Cooke et al., “Plasma concentrations of asymmetric dimethylarginine are increased in patients with type 2 diabetes mellitus,” *American Journal of Cardiology*, vol. 88, no. 10, pp. 1203–1205, 2001.

[26] M. C. Stühlinger, F. Abbasi, J. W. Chu et al., “Relationship between insulin resistance and an endogenous nitric oxide synthase inhibitor,” *Journal of the American Medical Association*, vol. 287, no. 11, pp. 1420–1426, 2002.

[27] M. C. Stühlinger, R. K. Oka, E. E. Graf et al., “Endothelial dysfunction induced by hyperhomocyst(e)inemia: role of asymmetric dimethylarginine,” *Circulation*, vol. 108, no. 8, pp. 933–938, 2003.

[28] H. Kawano, T. Motoyama, O. Hirashima et al., “Hyperglycemia rapidly suppresses flow-mediated endothelium-dependent vasodilation of brachial artery,” *Journal of the American College of Cardiology*, vol. 34, no. 1, pp. 146–154, 1999.

[29] F. Cosentino, K. Hishikawa, Z. S. Katusic, and T. F. Lüscher, “High glucose increases nitric oxide synthase expression and superoxide anion generation in human aortic endothelial cells,” *Circulation*, vol. 96, no. 1, pp. 25–28, 1997.

[30] N. N. Chan, P. Vallance, and H. M. Colhoun, “Endothelium-dependent and -independent vascular dysfunction in type 1 diabetes: role of conventional risk factors, sex, and glycemic control,” *Arteriosclerosis, Thrombosis, and Vascular Biology*, vol. 23, no. 6, pp. 1048–1054, 2003.

[31] K. Y. Lin, A. Ito, T. Asagami et al., “Impaired nitric oxide synthase pathway in diabetes mellitus: role of asymmetric dimethylarginine and dimethylarginine dimethylaminohydrolase,” *Circulation*, vol. 106, no. 8, pp. 987–992, 2002.

[32] M. I. Worthley, A. S. Holmes, S. R. Willoughby et al., “The deleterious effects of hyperglycemia on platelet function in diabetic patients with acute coronary syndromes mediation by superoxide production, resolution with intensive insulin administration,” *Journal of the American College of Cardiology*, vol. 49, no. 3, pp. 304–310, 2007.

[33] S. Yasuda, S. Miyazaki, M. Kanda et al., “Intensive treatment of risk factors in patients with type-2 diabetes mellitus is associated with improvement of endothelial function coupled with a reduction in the levels of plasma asymmetric dimethylarginine and endogenous inhibitor of nitric oxide synthase,” *European Heart Journal*, vol. 27, no. 10, pp. 1159–1165, 2006.

[34] M. A. Creager, S. J. Gallagher, X. J. Gireld, S. M. Coleman, V. J. Dzau, and J. P. Cooke, “L-Arginine improves endothelium-dependent vasodilation in hypercholesterolemic humans,” *Journal of Clinical Investigation*, vol. 90, no. 4, pp. 1248–1253, 1992.

[35] R. H. Boger and S. M. Bode-Boger, “Asymmetric dimethylarginine, derangements of the endothelial nitric oxide synthase pathway, and cardiovascular diseases,” *Seminars in Thrombosis and Hemostasis*, vol. 26, no. 5, pp. 539–545, 2000.

[36] J. R. Chan, R. H. Bögcr, S. M. Bode-Boger et al., “Asymmetric dimethylarginine increases mononuclear cell adhesiveness in hypercholesterolemic humans,” *Arteriosclerosis, Thrombosis, and Vascular Biology*, vol. 20, no. 4, pp. 1040–1046, 2000.

[37] R. H. Bögcr, K. Sydow, J. Borlak et al., “LDL cholesterol upregulates synthesis of asymmetrical dimethylarginine in human endothelial cells: involvement of S-adenosylmethionine-dependent methyltransferases,” *Circulation Research*, vol. 87, no. 2, pp. 99–105, 2000.

[38] A. Fard, C. H. Tuck, J. A. Donis et al., “Acute elevations of plasma asymmetric dimethylarginine and impaired endothelial function in response to a high-fat meal in patients with type 2 diabetes,” *Arteriosclerosis, Thrombosis, and Vascular Biology*, vol. 20, no. 9, pp. 2039–2044, 2000.

[39] A. Surdacki, M. Nowicki, J. Sandmann et al., “Reduced urinary excretion of nitric oxide metabolites and increased plasma levels of asymmetric dimethylarginine in men with essential hypertension,” *Journal of Cardiovascular Pharmacology*, vol. 33, no. 4, pp. 652–658, 1999.

[40] J. Sato, H. Masuda, S. Tamaoki et al., “Endogenous asymmetrical dimethylarginine and hypertension associated with puromycin nephrosis in the rat,” *British Journal of Pharmacology*, vol. 125, no. 3, pp. 469–476, 1998.

[41] R. J. Nijveldt, T. Teerlink, M. P. C. Siroen, A. A. Van Lambalgen, J. A. Rauwerda, and P. A. M. Van Leeuwen, “The liver is an important organ in the metabolism of asymmetrical dimethylarginine (ADMA),” *Clinical Nutrition*, vol. 22, no. 1, pp. 17–22, 2003.